Statera Biopharma, Inc. (STAB)
OTCMKTS: STAB · Delayed Price · USD
0.0006
-0.0001 (-14.29%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Statera Biopharma Revenue
Statera Biopharma had revenue of $670.47K in the quarter ending September 30, 2022, with 183.48% growth. This brings the company's revenue in the last twelve months to $3.69M, up 1,459.14% year-over-year. In the year 2021, Statera Biopharma had annual revenue of $1.49M.
Revenue (ttm)
$3.69M
Revenue Growth
+1,459.14%
P/S Ratio
0.01
Revenue / Employee
$80,166
Employees
46
Market Cap
42.85K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2021 | 1.49M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Dec 31, 2018 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSTAB News
- 1 year ago - Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs - GlobeNewsWire
- 1 year ago - Statera Biopharma Announces Completion of Application Process to Uplist to the OTCQB(R) Venture Marketplace - Accesswire
- 1 year ago - Statera Biopharma Receives Positive Nasdaq Listing Determination - Accesswire
- 1 year ago - Statera Biopharma Files Form 10-Q and Reaches Agreement with Silverback Capital and AVOF - Accesswire
- 1 year ago - Statera Biopharma Announces Signing of a Binding MOU with Holobeam Technologies to Gain Access to Holobeam's Disruptive Diagnostic Imaging and Therapeutic Technology for Cancer Patients - Accesswire
- 1 year ago - Statera Biopharma Completes Fiscal 2021 Audit; Files Form 10-K - Accesswire
- 2 years ago - Statera Biopharma Receives Nasdaq Listing Determination; Hearing Requested to Address Filing Delinquency - Accesswire
- 2 years ago - Statera Biopharma Receives Anticipated Notice of Additional Filing Delinquency from Nasdaq - Accesswire